# Phase 3 Open-label Study to Evaluate the Response and Safety of Kuvan® in Subjects With Phenylketonuria

> **NCT01732471** · PHASE3 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 90 (actual)

## Conditions studied

- Phenylketonuria

## Interventions

- **DRUG:** Kuvan®

## Key facts

- **NCT ID:** NCT01732471
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2014-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01732471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01732471, "Phase 3 Open-label Study to Evaluate the Response and Safety of Kuvan® in Subjects With Phenylketonuria". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT01732471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*